Informationen:
Fehler:
ID
36684
Beschreibung
Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR); ODM derived from: https://clinicaltrials.gov/show/NCT02293733
Link
https://clinicaltrials.gov/show/NCT02293733
Stichworte
Versionen (1)
- 01.06.19 01.06.19 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
1. Juni 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility NSCLC Non Small Cells Lung Cancer NCT02293733
Eligibility NSCLC Non Small Cells Lung Cancer NCT02293733
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility NSCLC Non Small Cells Lung Cancer NCT02293733
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Inclusion criteria
Item
inclusion criteria:
boolean
C1512693 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma | EGFR Activating Mutation
Item
nsclc patients with activating mutations of egfr
boolean
C0007131 (UMLS CUI [1])
C2984891 (UMLS CUI [2])
C2984891 (UMLS CUI [2])
First line treatment Tyrosine kinase inhibitor
Item
first-line treatment with a tki monotherapy
boolean
C1708063 (UMLS CUI [1,1])
C1268567 (UMLS CUI [1,2])
C1268567 (UMLS CUI [1,2])
Measurable lesion
Item
measurable lesion according to recist 1.1
boolean
C1513041 (UMLS CUI [1])
Age
Item
age> 18 years
boolean
C0001779 (UMLS CUI [1])
Resistance Secondary EGFR TKI | Resistance Acquired EGFR TKI
Item
secondary or acquired resistance of egfr tkis according to the jackman criteria
boolean
C0013203 (UMLS CUI [1,1])
C0175668 (UMLS CUI [1,2])
C1443775 (UMLS CUI [1,3])
C0013203 (UMLS CUI [2,1])
C0439661 (UMLS CUI [2,2])
C1443775 (UMLS CUI [2,3])
C0175668 (UMLS CUI [1,2])
C1443775 (UMLS CUI [1,3])
C0013203 (UMLS CUI [2,1])
C0439661 (UMLS CUI [2,2])
C1443775 (UMLS CUI [2,3])
First line treatment Tyrosine kinase inhibitor | Chemotherapy cycle Quantity
Item
patients for whom it was started a tki treatment in first line from january 2010 until june 2012 (patients who received 1 chemotherapy cycle could be included).
boolean
C1708063 (UMLS CUI [1,1])
C1268567 (UMLS CUI [1,2])
C1302181 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C1268567 (UMLS CUI [1,2])
C1302181 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
Exclusion Criteria
Item
exclusion criteria:
boolean
C0680251 (UMLS CUI [1])
Carcinoma, Small Cell
Item
patients with small cell carcinoma
boolean
C0262584 (UMLS CUI [1])
EGFR mutation Absent
Item
patients without egfr mutation
boolean
C3266992 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,2])
First line treatment EGFR Tyrosine kinase inhibitor Absent
Item
patients not treated with egfr tki in first line treatment
boolean
C1708063 (UMLS CUI [1,1])
C1443775 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C1443775 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
Measurable lesion Absent
Item
not measurable lesion to recist 1.1
boolean
C1513041 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,2])